# Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine

Study · id `cardio:ct-nct02294474` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02294474](<https://clinicaltrials.gov/study/NCT02294474>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02294474

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 505 participants.

## Technical summary

Registry record NCT02294474. Randomized; no masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2016-02 (actual). Results posted on 2018-01-18.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 505 participants (enrolled count; ClinicalTrials.gov record NCT02294474, source copy `cardio:ctgov-nct02294474-2018-01-18`, retrieved 2026-10-26)
- Start date: 2015-01 (registry gives no type) (ClinicalTrials.gov record NCT02294474, source copy `cardio:ctgov-nct02294474-2018-01-18`, retrieved 2026-10-26)
- Primary completion: 2016-02 (actual) (ClinicalTrials.gov record NCT02294474, source copy `cardio:ctgov-nct02294474-2018-01-18`, retrieved 2026-10-26)
- Completion: 2016-02 (actual) (ClinicalTrials.gov record NCT02294474, source copy `cardio:ctgov-nct02294474-2018-01-18`, retrieved 2026-10-26)
- Results first posted: 2018-01-18 (ClinicalTrials.gov record NCT02294474, source copy `cardio:ctgov-nct02294474-2018-01-18`, retrieved 2026-10-26)
- Countries: United States; Argentina; Chile; Colombia; Germany; Hungary; Italy; Romania; Russia; South Korea; Spain; Türkiye (ClinicalTrials.gov record NCT02294474, source copy `cardio:ctgov-nct02294474-2018-01-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02294474-2018-01-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine
- Acronym: SORELLA2
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): SAR342434
- Intervention (Drug): Humalog
- Intervention (Drug): insulin glargine HOE901
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study (`cardio:pubmed-29232162`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0333e46947be2e07b3f34b8094d2e548152e0e589b3b1ec33187ad84d3ea7bc9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
